Meitheal Pharmaceuticals Receives Exclusive Commercial Rights of Three Biosimilars Across the US
Shots:
- Meitheal Pharmaceuticals & its parent, Hong Kong King-Friend Industry (HKF), have entered into an exclusive licensing agreement for commercializing biosimilars of pegfilgrastim & filgrastim in oncology and follitropin alpha for fertility treatment in the US
- Pegfilgrastim (SC, once per cycle) & filgrastim (SC, IV, daily for 14 days in CT treatment cycle) are bone marrow stimulants which enhance WBC production in cancer patients by binding to G-CSF receptors, stimulating neutrophil proliferation & activation against infection
- Follitropin alpha is a recombinant human follicle-stimulating hormone (FSH) used to promote follicle development in women & spermatogenesis in men during fertility treatments
Ref: Businesswire | Image: Meitheal
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
